Showing results (1-10 of 184) with videos related to
Sort By:
Pageof 19
Bioorganic & Medicinal Chemistry|November 5, 1998
XH-14 analogues as adenosine antagonistsP J Scammells, S P Baker, A R BeaugleholeJournal of Medicinal Chemistry|January 11, 2001
Fluorosulfonyl-substituted xanthines as selective irreversible antagonists for the A(1)-adenosine receptorA R Beauglehole, S P Baker, P J ScammellsBritish Journal of Pharmacology|July 6, 2000
Differential A(1)-adenosine receptor reserve for inhibition of cyclic AMP accumulation and G-protein activation in DDT(1) MF-2 cellsS P Baker, P J Scammells, L BelardinelliBioorganic & Medicinal Chemistry Letters|May 7, 1999
Adenosine receptor ligands with oxygenated N6-substituentsS A Hutchinson, S P Baker, P J ScammellsJournal of Medicinal Chemistry|August 19, 1994
Substituted 1,3-dipropylxanthines as irreversible antagonists of A1 adenosine receptorsP J Scammells, S P Baker, L Belardinelli, et al.Bioorganic & Medicinal Chemistry Letters|February 6, 1999
N6-(5,6-epoxynorbornyl)adenosine analogs as A1 adenosine agonistsD M Wright, S P Baker, S G Stewart, et al.Molecular Pharmacology|July 1, 1996
A novel irreversible antagonist of the A1-adenosine receptorM Srinivas, J C Shryock, P J Scammells, et al.The Journal of Pharmacology and Experimental Therapeutics|December 1, 1995
1,3-Dipropyl-8-[2-(5,6-epoxy)norbornyl]xanthine, a potent, specific and selective A1 adenosine receptor antagonist in the guinea pig heart and brain and in DDT1MF-2 cellsL Belardinelli, J C Shryock, Y Zhang, et al.Current Pharmaceutical Design|July 29, 2004
A(1) adenosine receptor agonists: medicinal chemistry and therapeutic potentialS A Hutchinson, P J ScammellsCurrent Medicinal Chemistry|February 19, 2014
The dopamine D2 and adenosine A2A receptors: past, present and future trends for the treatment of Parkinson's diseaseM Jorg, P J Scammells, B CapuanoPageof 19